Beigene, Ltd. (NASDAQ:ONC) Insider Xiaodong Wang Sells 41,760 Shares

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $261.28, for a total value of $10,911,052.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The shares were sold at an average price of $254.58, for a total value of $2,073,808.68.

Beigene Stock Down 1.4 %

ONC traded down $3.67 during trading on Thursday, reaching $262.59. 209,100 shares of the company’s stock were exchanged, compared to its average volume of 444,738. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The company has a market capitalization of $25.70 billion, a P/E ratio of -31.87, a P/E/G ratio of 7.73 and a beta of 0.65.

Beigene (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.09 billion. On average, analysts anticipate that Beigene, Ltd. will post -5.82 EPS for the current year.

Analyst Ratings Changes

ONC has been the topic of several research analyst reports. JMP Securities set a $348.00 price target on Beigene in a research report on Friday, February 28th. Bank of America raised Beigene from a “neutral” rating to a “buy” rating and raised their price target for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Guggenheim reaffirmed a “buy” rating on shares of Beigene in a research report on Friday, February 28th. Macquarie lifted their target price on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Finally, Sanford C. Bernstein set a $259.00 price target on Beigene in a research note on Thursday, March 13th.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.